Innovation Pharmaceuticals Inc (IPIX)

[threebabiesbusy]

Key statements in this paragraph….

Competitive Positioning: Brilacidin’s oral sachet formulation was perceived as convenient and highly preferred by key opinion leaders (KOLs) in comparison to intravenous (IV) options, and KOLs are willing to prescribe Brilacidin for all HNC patients because the compound’s preventative properties and ease of use as an oral rinse. Brilacidin has the potential to be a first-line product for prevention and treatment of SOM due to efficacy perceived as being highly clinically meaningful.